The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma

European Respiratory Journal

Volumn 21, Issue 2, 2003, Pages 287-293

  Camporota, L ^a   Corkhill, A ^a   Long, H ^a   Lordan, J ^a   Stanciu, L ^a   Tuckwell, N ^d   Cross, A ^b   Stanford, J L ^c   Rook, G A W ^c   Holgate, S T ^a   Djukanovic, R ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b GNB Limited   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d NONE

Author keywords

Allergen challenge; Asthma; Interleukin 5; Mycobacterium vaccae

Indexed keywords

ALLERGEN; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYTOKINE; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; INTERLEUKIN 13; INTERLEUKIN 5; PLACEBO; SRL 172; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ASTHMA; ARTICLE; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; MALE; MYCOBACTERIUM VACCAE; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TH2 CELL;

EID: 12244290348     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00042103     Document Type: Article

References (29)

1. Romagnani S. Regulation of the development of type 2 T-helper cells in allergy. Curr Opin Immunol 1994; 6: 838-846.
2. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304.
3. Holt PG. Environmental factors and primary T-cell sensitisation to inhalant allergens in infancy: reappraisal of the role of infections and air pollution. Pediatr Allergy Immunol 1995; 6: 1-10.
4. Bjorksten B. Risk factors in early childhood for the development of atopic diseases. Allergy 1994; 49: 400-407.
5. Holt PG. Infections and the development of allergy. Toxicol Lett 1996; 86: 205-210.
6. Matricardi PM, Rosmini F, Riondino S, et al. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ 2000; 320: 412-417.
7. Rook GA, Stanford JL. Give us this day our daily germs. Immunol Today 1998; 19: 113-116.
8. Roman M, Martin Orozco E, Goodman S, et al. E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3: 849-854.
9. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997; 275: 77-79.
10. Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-specific T-cell memory in atopic and normal children. Lancet 1999; 353: 196-200.
11. Martinez ED, Holt PG. Role of microbial burden in aetiology of allergy and asthma. Lancet 1999; 354: Suppl. 2, SII12-SII15.
12. Johnson JL, Kamya RM, Okwera A, et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non human immunodeficiency virus infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Ungandan-Case Western Reserve University Research Collaboration. J Infect Dis 2000; 181: 1304-1312.
13. Maraveyas A, Baban B, Kennard D, et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 1999; 10: 817-824.
14. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998; 82: 568-573.
15. Assersohn L, Souberbielle BE, O'Brien ME, et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin Oncol (R Coll Radiol) 2002; 14: 23-27.
16. O'Brien ME, Saini A, Smith IE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000; 83: 853-857.
17. Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 1998; 93: 307-313.
18. Zuany-Amorim C, Sawicka E, Manlius C, et al. IL-10 and TGF-β mediated suppression of airway eosinophilia by allergen-specific regulatory CD4+ CD45RBlow T cells induced by SRP299 (killed Mycobacterium vaccae). Nat Med 2002; 8: 625-629.
19. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336: 1338-1342.
20. Inman MD, Watson R, Cockcroft DW, Wong BJ, Hargreave FE, O'Byrne PM. Reproducibility of allergen-induced early and late asthmatic responses. J Allergy Clin Immunol 1995; 95: 1191-1195.
21. Shirtcliffe PM, Easthope SE, Cheng S, et al. The effect of delipidated deglycolipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am J Respir Crit Care Med 2001; 163: 1410-1414.
22. Hopfenspirger MT, Parr SK, Hopp RJ, Townley RG, Agrawal DK. Mycobacterial antigens attenuate late phase response, airway hyperresponsiveness, and bronchoalveolar lavage eosinophilia in a mouse model of bronchial asthma. Int Immunopharmacol 2001; 1: 1743-1751.
23. Hopfenspirger MT, Agrawal DK. Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. J Immunol 2002; 168: 2516-2522.
24. Hopkin JM, Shaldon S, Ferry B, et al. Mycobacterial immunisation in grass pollen asthma and rhinitis. Thorax 1998; 53: Suppl. 4, 63.
25. Arkwright PD, David TJ. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001; 107: 531-534.
26. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-2148.
27. Adams JF, Scholvinck EH, Gie RP, Potter PC, Beyers N, Beyers AD. Decline in total serum IgE after treatment for tuberculosis. Lancet 1999; 353: 2030-2033.
28. Abou-Zeid C, Gares MP, Inwald J, et al. Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun 1997; 65: 1856-1862.
29. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001; 31: 1122-1131.